ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,416.00
0.68%
S&P ASX All Technology
3,926.50
0.89%
Brent Oil
72.37
-0.11%
US Dollar vs AUD
1.54341
-0.07%
Bitcoin
92,707.51
0.80%
Pepperstone
Advertisement
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Virios Therapeutics Inc (VIRI)

  7. Virios Therapeutics Inc (VIRI) News

VIRI

Virios Therapeutics (VIRI)

Virios Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:VIRI
DateTimeSourceHeadlineSymbolCompany
22/11/202401:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRIVirios Therapeutics Inc
09/11/202400:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VIRIVirios Therapeutics Inc
07/11/202423:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRIVirios Therapeutics Inc
31/10/202400:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRIVirios Therapeutics Inc
18/10/202407:30Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VIRIVirios Therapeutics Inc
18/10/202407:29Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VIRIVirios Therapeutics Inc
16/10/202407:19Edgar (US Regulatory)Form SC 13D - General Statement of Acquisition of Beneficial OwnershipNASDAQ:VIRIVirios Therapeutics Inc
07/10/202423:06Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:VIRIVirios Therapeutics Inc
07/10/202423:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRIVirios Therapeutics Inc
07/10/202422:05GlobeNewswire Inc.Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)NASDAQ:VIRIVirios Therapeutics Inc
10/08/202400:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VIRIVirios Therapeutics Inc
08/08/202423:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRIVirios Therapeutics Inc
08/08/202423:15GlobeNewswire Inc.Virios Therapeutics Announces Second Quarter 2024 Financial ResultsNASDAQ:VIRIVirios Therapeutics Inc
01/08/202423:41GlobeNewswire Inc.Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024NASDAQ:VIRIVirios Therapeutics Inc
23/07/202423:15GlobeNewswire Inc.Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne CenterNASDAQ:VIRIVirios Therapeutics Inc
20/06/202423:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRIVirios Therapeutics Inc
12/06/202423:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRIVirios Therapeutics Inc
23/05/202403:30GlobeNewswire Inc.Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b StudyNASDAQ:VIRIVirios Therapeutics Inc
21/05/202406:05Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:VIRIVirios Therapeutics Inc
20/05/202423:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRIVirios Therapeutics Inc
20/05/202410:53GlobeNewswire Inc.Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b StudyNASDAQ:VIRIVirios Therapeutics Inc
18/05/202406:10GlobeNewswire Inc.Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b StudyNASDAQ:VIRIVirios Therapeutics Inc
18/05/202406:01Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:VIRIVirios Therapeutics Inc
11/05/202400:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VIRIVirios Therapeutics Inc
09/05/202422:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRIVirios Therapeutics Inc
09/05/202421:45GlobeNewswire Inc.Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:VIRIVirios Therapeutics Inc
08/05/202407:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRIVirios Therapeutics Inc
02/05/202423:15GlobeNewswire Inc.Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024NASDAQ:VIRIVirios Therapeutics Inc
27/03/202400:15GlobeNewswire Inc.Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVIDNASDAQ:VIRIVirios Therapeutics Inc
09/03/202409:00Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:VIRIVirios Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:VIRI

Your Recent History

FX
AUDCAD
AUD vs CAD
ASX
QBE
QBE Insurance
COIN
SOLUSD
Solana
NYSE
XOM
Exxon Mobil
ASX
WDC
Westfield
FTSE
UKX
FTSE 100
SPI
SP500
S&P 500
ASX
RIO
Rio Tinto
ASX
XMM
S&P ASX 300 Metals and M...
NYSE
NKE
Nike
ASX
WOW
Woolworths
ASX
WBC
Westpac Banking
NASDAQ
AMZN
Amazon.com
COIN
XRPUSD
Ripple
ASX
WES
Wesfarmers
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 60%* for ASX Level 1 & 2

1 year 40%, 2 years 40% and *3 years 60%

*Across 3 years $1958.40 only $783.36